HLS Therapeutics Inc. (TSX:HLS)
Canada · Delayed Price · Currency is CAD 3.790
+0.090 (2.43%)
Aug 28, 2026, 3:59 PM EST
HLS Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 56.24 | 55.5 | 56.62 | 63.07 | 61.47 | 60.01 | |
Revenue Growth | -0.32% | -1.98% | -10.23% | 2.61% | 2.43% | 6.95% |
Cost of Revenue | 16.83 | 15.79 | 14.66 | 13.2 | 10.71 | 9.65 |
Gross Profit | 39.41 | 39.71 | 41.96 | 49.88 | 50.76 | 50.36 |
Selling, General & Admin | 20.65 | 20.09 | 25.31 | 28.82 | 26.93 | 24.02 |
Operating Expenses | 43.92 | 43.82 | 49.65 | 60.23 | 64.26 | 56.64 |
Operating Income | -4.51 | -4.11 | -7.69 | -10.35 | -13.5 | -6.28 |
Interest Expense | -4.89 | -7.09 | -10.08 | -8.75 | -7.32 | -6.96 |
Interest & Investment Income | 0.06 | 0.11 | 0.32 | 0.35 | 0.06 | 0.04 |
Currency Exchange Gain (Loss) | 1.33 | -0.41 | -0 | 0.05 | -0.11 | -0.41 |
Other Non Operating Income (Expenses) | -1.21 | -1.38 | -0.99 | -1.73 | 1.54 | 1.8 |
EBT Excluding Unusual Items | -9.22 | -12.88 | -18.44 | -20.43 | -19.33 | -11.81 |
Gain (Loss) on Sale of Assets | - | - | 3.38 | - | - | - |
Asset Writedown | - | - | - | -3.89 | -3.05 | - |
Other Unusual Items | - | - | -0.52 | -3.48 | -1.34 | - |
Pretax Income | -9.22 | -12.88 | -15.58 | -27.8 | -23.72 | -11.81 |
Income Tax Expense | -0.65 | -0.45 | 4.07 | -0.27 | -0.12 | 1.31 |
Net Income | -8.57 | -12.43 | -19.66 | -27.53 | -23.6 | -13.12 |
Net Income to Common | -8.57 | -12.43 | -19.66 | -27.53 | -23.6 | -13.12 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 31 | 32 | 32 | 32 | 32 | 32 |
Shares Outstanding (Diluted) | 31 | 32 | 32 | 32 | 32 | 32 |
Shares Change | -1.42% | -0.98% | -1.31% | -0.52% | 0.77% | 1.48% |
EPS (Basic) | -0.27 | -0.39 | -0.62 | -0.85 | -0.73 | -0.41 |
EPS (Diluted) | -0.27 | -0.39 | -0.62 | -0.85 | -0.73 | -0.41 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 18.15 | 16.93 | 7.99 | 15.75 | 16.9 | 16.38 |
Free Cash Flow Per Share | 0.58 | 0.54 | 0.25 | 0.49 | 0.52 | 0.51 |
Dividend Per Share | - | - | - | 0.076 | 0.148 | 0.158 |
Dividend Growth | - | - | - | -48.76% | -6.50% | 0.69% |
Gross Margin | 70.07% | 71.55% | 74.11% | 79.07% | 82.58% | 83.92% |
Operating Margin | -8.02% | -7.40% | -13.58% | -16.41% | -21.96% | -10.47% |
Profit Margin | -15.24% | -22.40% | -34.71% | -43.65% | -38.39% | -21.86% |
Free Cash Flow Margin | 32.28% | 30.50% | 14.11% | 24.97% | 27.49% | 27.30% |
EBITDA | 17.01 | 17.19 | 14.56 | 21.52 | 20.8 | 23.4 |
EBITDA Margin | 30.24% | 30.98% | 25.71% | 34.13% | 33.83% | 39.00% |
D&A For EBITDA | 21.52 | 21.3 | 22.24 | 31.87 | 34.29 | 29.69 |
EBIT | -4.51 | -4.11 | -7.69 | -10.35 | -13.5 | -6.28 |
EBIT Margin | -8.02% | -7.40% | -13.58% | -16.41% | -21.96% | -10.47% |